Antithrombotic Strategies in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systemic Review and Network Meta-Analysis of Randomized Controlled Trials

Figure 1. Flow diagram of included studies.

Figure 2. Network of four antithrombotic therapy strategies. The nodes represent the antithrombotic therapy strategies to be compared; the size of nodes is proportional to the number of patients included for the different antithrombotic therapy strategies. The edges represent the direct comparisons between the antithrombotic therapy strategies and the thickness is proportional to the sample size of the studies.

Figure 3. Forest plots for safety outcomes. Odds ratio and 95% credible intervals (CrI) compared with vitamin antagonist (VKA) plus dual antiplatelet therapy (DAPT) are plotted. The estimated between-trial effect heterogeneity and its 95% CrI (in standard deviation of the log odds ratio scale) from network meta-analysis for each outcome is (A) TIMI major bleeding, 0.22 (95% CrI, 0.10–0.55), I2 = 0%; (B) TIMI major and minor bleeding, 0.46 (95% CrI, 0.09–0.84), I2 = 60%; (C) Trial-defined primary safety outcome, 0.48 (95% CrI, 0.08–1.08), I2 = 70%; (D) Intracranial hemorrhage, 0.41 (95% CrI, 0.26–1.08), I2 = 0%. DAPT, dual antiplatelet therapy; NOAC, non-vitamin K antagonist oral anticoagulant; SAPT, single antiplatelet therapy; VKA, vitamin K antagonist.

Figure 4. Forest plots for efficacy outcomes. Odds ratio and 95% credible intervals (CrI) compared with vitamin antagonist (VKA) plus dual antiplatelet therapy (DAPT) are plotted. The estimated between-trial effect heterogeneity and its 95% CrI (in standard deviation of the log odds ratio scale) from network meta-analysis for each outcome is (A) Trial-defined primary MACEs, 0.23 (95% CrI, 0.09–0.55), I2 = 7%; (B) All-cause death, 0.24 (95% CrI, 0.13–0.60), I2 = 0%; (C) Cardiovascular death, 0.17 (95% CrI, 0.12–0.46), I2 = 0%; (D) Myocardial infarction, 0.15 (95% CrI, 0.05–0.35), I2 = 0%. (E) Stroke, 0.41 (95% CrI, 0.06–0.90), I2 = 0%; (F) Stent thrombosis, 0.30 (95% CrI, 0.09–0.69), I2 = 0%. MACEs: major adverse cardiovascular events; DAPT: dual antiplatelet therapy; NOAC: non-vitamin K antagonist oral anticoagulant; SAPT: single antiplatelet therapy; VKA: vitamin K antagonist.

Figure 5. Odds ratio (OR) for TIMI major bleeding and the trial defined major adverse cardiovascular events (MACE).